Alpha-2-Macroglobulin
EmergingAlpha-2-macroglobulin is a component of the FibroTest composite panel, a noninvasive alternative to liver biopsy for fibrosis staging.
This protein blocks certain enzymes and rises during inflammation. It's one ingredient in a commercial blood test panel that estimates liver scarring without needing a biopsy, combining several different blood markers together into one composite score.
Alpha-2-macroglobulin is a broad-spectrum protease inhibitor and acute-phase protein produced mainly by the liver.
It's one of the components in FibroTest/FibroSure, a commercial composite blood panel used as a noninvasive alternative to liver biopsy for staging fibrosis in chronic hepatitis and other liver diseases.
Measured via serum immunoassay as part of the FibroTest panel, combined mathematically with haptoglobin, bilirubin, GGT, and apolipoprotein A1 (all discussed elsewhere in this biomarker set) to generate a composite fibrosis stage estimate.
A FibroTest result suggesting significant fibrosis may prompt closer monitoring, antiviral treatment initiation (in viral hepatitis), or specialist referral, offering a noninvasive alternative to biopsy for many patients, similar in spirit to the FIB-4 index discussed earlier for AST/ALT-based fibrosis assessment.
Works alongside several other markers (haptoglobin, bilirubin, GGT, ApoA1) as part of a combined fibrosis risk score.
- General hepatology reference literature on FibroTest/FibroSure composite liver fibrosis panels.